Skip to main content
. 2019 Oct 29;51(2):271–280. doi: 10.1111/apt.15555

Figure 1.

Figure 1

(A) Overview of the phase 3 OCTAVE programme, and treatment sequences for patients in (B) the tofacitinib maintenance remitter dose de‐escalation subpopulation and (C) the tofacitinib maintenance failure dose escalation subpopulation. OCTAVE Open is ongoing; data as of November 2017 data cut‐off. b.d., twice daily; N, number of patients included in each treatment group or subpopulation